NCT04422522

Fibromyalgia During the COVID-19 Pandemic

Status unknown Last updated 11 June 2020

What this trial tests

trial in Fibromyalgia, Primary in 45 participants. Status unknown.

Timeline

15 March 2020

Primary endpoint
15 May 2020

30 June 2020

Quick facts

Lead sponsor	Al-Azhar University
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	45
Start date	15 March 2020
Primary completion	15 May 2020
Estimated completion	30 June 2020
Sites	1 location across Egypt

Conditions studied

• Fibromyalgia, Primary — all drugs for Fibromyalgia, Primary →

Sponsor

Al-Azhar University

Who can join

19 and older, any sex, with Fibromyalgia, Primary. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

On 12 January 2020, the World Health Organization (WHO) confirmed that a novel coronavirus was the cause of a respiratory illness in a cluster of people in Wuhan City, Hubei Province, China, which was reported to the WHO on 31 December 2019.

There is evidence of a high prevalence of psychiatric comorbidities in Fibromyalgia (FM )(especially depression, anxiety, post-traumatic stress disorder), which are associated with a worse clinical profile.

In these challenging times of COVID-19, anxiety increased among the general population. Fibromyalgia patients are more at risk of developing anxiety in these difficult times. This might result in more frequent visits to the rheumatology clinics with an exacerbation of their chronic pain syndrome.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. [Fibromyalgia in the new era of SARS-CoV-2 infection and post-COVID-19 syndrome: A scoping review].
   Tuta-Quintero E, Mora-Karam C, Pimentel J. · · 2022 · PMID 40477972 · DOI 10.1016/j.rcreu.2022.03.008